FDA expresses doubts about evidence on anemia drugs

09/10/2007 | Wall Street Journal (free content), The

The FDA discovered "important deficiencies" in data that support the beneficial effects of anemia treatment drugs Epogen and Aranesp made by Amgen and Procrit made by Johnson & Johnson. Studies that support quality-of-life improvement claims are limited and may not comply with current regulatory requirements, the FDA commented. More research is required to develop safer dosing recommendations, according to the FDA.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC